ORXOY (Orexo AB) Owner Earnings per Share (TTM): 2.08 (As of Jun. 2026) — 78% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORXOY Orexo AB ORXOY
37 GF Score
Price $1.80
GF Value $0.31
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Orexo AB Owner Earnings per Share (TTM)?

Orexo AB ORXOY -14.29% 37 Owner Earnings per Share (TTM) is 2.08 as of Jun. 2026, which is 78% below its 10-year median of 9.40. GuruFocus rates ORXOY with a GF Score™ of 37/100 and a GF Value™ of $0.31 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 476 Drug Manufacturers companies, Orexo AB ranks better than 99.16% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Orexo AB's Owner Earnings per Share (TTM) ended in Jun. 2026 was $2.08. It's Price-to-Owner-Earnings ratio for today is 0.87.


The historical rank and industry rank for Orexo AB's Owner Earnings per Share (TTM) or its related term are showing as below:

ORXOY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0.87   Med: 9.4   Max: 46.71
Current: 0.87


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Orexo AB was 46.71. The lowest was 0.87. And the median was 9.40.


ORXOY's Price-to-Owner-Earnings is ranked better than
99.16% of 476 companies
in the Drug Manufacturers industry
Industry Median: 23.845 vs ORXOY: 0.87

Orexo AB's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was $-0.31. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.17. It's PE Ratio (TTM) ratio for today is At Loss.

Orexo AB's EPS without NRI for the three months ended in Jun. 2026 was $-0.31. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.08. It's PE Ratio without NRI ratio for today is At Loss.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Orexo AB Owner Earnings per Share (TTM) Related Terms


Orexo AB Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Orexo AB's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orexo AB Owner Earnings per Share (TTM) Chart

Orexo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.71 -0.32 -0.47 -0.31 1.84

Orexo AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.13 1.84 2.28 1.49

ORXOY vs ZTS, UTHR: Owner Earnings per Share (TTM) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orexo AB Price-to-Owner-Earnings vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Orexo AB's Price-to-Owner-Earnings falls into.


ORXOY
37GF Score
Orexo AB ORXOY
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orexo AB Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Orexo AB's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income 49.89
Depreciation, Depletion and Amortization 6.58
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 1.81
Change In Working Capital 21.75
Shares Outstanding (Diluted Average) 39.61

1. Start with "Net Income" from income statement. Orexo AB's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was $49.89 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Orexo AB's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Jun. 2026 was $6.58 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Orexo AB's Change In Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $1.81 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Orexo AB's 5-Year Average Maintenance Capital Expenditure = $1.81 Mil

5. "Change In Working Capital" is from cashflow statement. Orexo AB's Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2026 was $21.75 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Orexo AB's Shares Outstanding (Diluted Average) for the months ended in Jun. 2026 was 39.607 Mil.

Orexo AB's Onwer Earnings Per Share for Jun. 2026 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 49.889 +6.584+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-1.814384158586+21.747)/39.607
=2.08

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=1.80/2.08
=0.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of 2.08 mean?
Orexo AB (ORXOY) has a Owner Earnings per Share (TTM) of 2.08 as of Jun. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Orexo AB. This is 78% below median its historical median of 9.40. Over the past decade, Orexo AB's Owner Earnings per Share (TTM) has ranged from 0.87 to 46.71. According to the industry distribution chart, Orexo AB ranks #4 out of 476 companies in the Drug Manufacturers industry, placing it in the top 0.8%.
Is Orexo AB's Owner Earnings per Share (TTM) too high?
Orexo AB's current Owner Earnings per Share (TTM) of 2.08 is 78% below median its 10-year median of 9.40. Over the past 10 years, this metric has ranged from a low of 0.87 to a high of 46.71. The Drug Manufacturers industry median Owner Earnings per Share (TTM) is 23.85. Orexo AB's value of 2.08 is 91.3% below this industry median. Based on the distribution chart, Orexo AB ranks #4 out of 476 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orexo AB has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Owner Earnings per Share (TTM) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orexo AB ranks #4 out of 476 companies for Owner Earnings per Share (TTM). This places Orexo AB in the top 1% of its industry — outperforming the majority of peers. The industry median Owner Earnings per Share (TTM) is 23.85. Orexo AB's value of 2.08 is 91.3% below this benchmark. Historically, Orexo AB's own Owner Earnings per Share (TTM) has ranged from 0.87 to 46.71 over the past decade. While the company's 10-year median is 9.40 vs. the industry median of 23.85, Orexo AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Drug Manufacturers company?
The median Owner Earnings per Share (TTM) among Drug Manufacturers companies is 23.85, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orexo AB's current Owner Earnings per Share (TTM) of 2.08 is 91.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Orexo AB. For the Drug Manufacturers industry, the median Owner Earnings per Share (TTM) is 23.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orexo AB's current Owner Earnings per Share (TTM) is 2.08, which is 78% below median its own 10-year median of 9.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOY) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.31, compared to a current price of $1.80 — trading 480.6% above its estimated fair value. The current Owner Earnings per Share (TTM) is 2.08, which is 78% below median its 10-year median of 9.40 and 91.3% below the Drug Manufacturers industry median of 23.85. Orexo AB's overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Orexo AB (ORXOY), the current Owner Earnings per Share (TTM) is 2.08 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orexo AB (ORXOY) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of $1.80 is trading 480.6% above its estimated GF Value™ of $0.31. GuruFocus considers Orexo AB to be Significantly Overvalued.

Key valuation signals for ORXOY:

  • Owner Earnings per Share (TTM): 2.08 (78% below median its 10-year median of 9.40)
  • GF Value™: $0.31 vs. price of $1.80 (480.6% above fair value)
  • GF Score™: 37/100 with 7 warning signs
  • Industry Position: 91.3% below the Drug Manufacturers median (#4 of 476)

No single metric tells the full story. See the ORXOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orexo AB Business Description

Address Virdings alle 22, Uppsala, SWE, 75105
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
37GF Score

Get the complete analysis for ORXOY

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.80
Price
$0.31
GF Value